Time-course Analysis Reveals That Corticosteroids Resuscitate Diminished CD8+ T Cells in COVID-19: a Retrospective Cohort Study
Overview
Authors
Affiliations
Objective: To illustrate the effect of corticosteroids and heparin, respectively, on coronavirus disease 2019 (COVID-19) patients' CD8+ T cells and D-dimer.
Methods: In this retrospective cohort study involving 866 participants diagnosed with COVID-19, patients were grouped by severity. Generalized additive models were established to explore the time-course association of representative parameters of coagulation, inflammation and immunity. Segmented regression was performed to examine the influence of corticosteroids and heparin upon CD8+ T cell and D-dimer, respectively.
Results: There were 541 moderate, 169 severe and 156 critically ill patients involved in the study. Synchronous changes of levels of NLR, D-dimer and CD8+ T cell in critically ill patients were observed. Administration of methylprednisolone before 14 DFS compared with those after 14 DFS ( = 0.154%, 95% CI=(0, 0.302), =.048) or a dose lower than 40 mg per day compared with those equals to 40 mg per day ( = 0.163%, 95% CI=(0.027, 0.295), =.020) significantly increased the rising rate of CD8+ T cell in 14-56 DFS.
Conclusions: The parameters of coagulation, inflammation and immunity were longitudinally correlated, and an early low-dose corticosteroid treatment accelerated the regaining of CD8+ T cell to help battle against SARS-Cov-2 in critical cases of COVID-19.
Choi K, Kim D, Jin K, Lee H, Park T, Ryu B Ann Med. 2022; 54(1):2998-3006.
PMID: 36453635 PMC: 9721443. DOI: 10.1080/07853890.2022.2137736.
Mo Y, To K, Zhou R, Liu L, Cao T, Huang H Front Immunol. 2022; 12:799896.
PMID: 35095881 PMC: 8795605. DOI: 10.3389/fimmu.2021.799896.
Prognostic value of lymphocyte count in severe COVID-19 patients with corticosteroid treatment.
Lu C, Chen B, Yang H, Hu H, Liu Y, Zhao Y Signal Transduct Target Ther. 2021; 6(1):106.
PMID: 33654057 PMC: 7921828. DOI: 10.1038/s41392-021-00517-3.
Oz M, Lorke D, Kabbani N Pharmacol Ther. 2020; 221:107750.
PMID: 33275999 PMC: 7854082. DOI: 10.1016/j.pharmthera.2020.107750.